Back to top

Accenture Brings Open Partner Ecosystem for Drug Discovery

Read MoreHide Full Article

Accenture plc (ACN - Free Report) has modeled an open partner ecosystem, aimed at helping independent software vendors (ISVs) and life sciences companies collaborate to speed up and enhance drug discovery.

The ecosystem is an integral part of the cloud-based informatics research platform, which is being developed by Accenture in collaboration with Merck (MRK - Free Report) on Amazon’s (AMZN - Free Report) Amazon Web Services (“AWS”). The platform enables scientific research-based organizations in the life sciences industry to quickly access, aggregate and analyze research data from multiple applications. It facilitates easier collaboration across the R&D enterprise, including external partners.

The new ecosystem will enable ISVs leverage the platform’s use of open, industry-standard-based application programming interfaces (APIs) to integrate technology components, applications and content into the platform.

As a result, life sciences companies will be able to provide researchers access to innovative capabilities such as small-molecule and biological-entity registration, biological assay data capture, genomics data analysis, image storage and analysis and artificial intelligence.

In the past year, shares of Accenture have gained 7% compared with the 1.7% rise of the Zacks S&P 500 composite.

 

To Conclude

We believe that the latest move will help Accenture boost its Products segment as it comprises the Life Sciences industry group, which serves pharmaceutical, medical technology and biotechnology companies. Performance of this segment was particularly strong in the last reported quarter, with revenues increasing 12% on a year-over-year basis.

Zacks Rank & Stocks to Consider

Accenture currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

A better-ranked stock in the broader Zacks Business Services sector is WEX Inc. (WEX - Free Report) , carrying a Zacks Rank #2 (Buy). The long-term expected EPS (three to five years) growth rates for WEX is 15%.

The Hottest Tech Mega-Trend of All

Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Amazon.com, Inc. (AMZN) - free report >>

Merck & Co., Inc. (MRK) - free report >>

WEX Inc. (WEX) - free report >>

Accenture PLC (ACN) - free report >>

More from Zacks Analyst Blog

You May Like